DIP2A-IT1: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Target Name: DIP2A-IT1

NCBI ID: G100862692

DIP2A-IT1

Other Name(s): DIP2A intronic transcript 1 (non-protein coding) | DIP2A intronic transcript 1

DIP2A-IT1: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Inflammatory neurodegenerative diseases, such as multiple sclerosis (MS) and Alzheimer's disease, are characterized by the progressive destruction of nerve cells and the formation of immune complexes, leading to a build-up of neurotoxins and an exacerbation of symptoms. The most effective treatments for these diseases are currently focused on managing symptoms and improving quality of life, rather than curing the underlying disease. Therefore, identifying new drug targets and biomarkers is a promising approach to develop new treatments for these debilitating conditions.

DIP2A-IT1 is a protein that has been identified as a potential drug target and biomarker for inflammatory neurodegenerative diseases. Its unique structure and function make it an attractive target for drug development.

Structure and Function of DIP2A-IT1

DIP2A-IT1 is a 21-kDa protein that is expressed in various tissues, including brain, spleen, and pancreas. It is composed of two distinct domains: a N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal domain consists of a unique farnesylated cysteine residue, which is known to be a critical site for protein-protein interactions and may play a role in the regulation of cellular processes. The C-terminal domain contains a single cysteine residue, which may be involved in the regulation of the protein's stability or localization to the plasma membrane.

The function of DIP2A-IT1 is still being studied, but its involvement in the regulation of cellular processes and its potential as a drug target is clear. DIP2A-IT1 has been shown to play a role in the regulation of inflammation and neurodegeneration. It has been shown to interact with various proteins, including nuclear factor kappa B (NF-kappa-B), which is a well-known regulator of inflammation and neurodegeneration.

Drug Target Potential

The drug target potential of DIP2A-IT1 is high due to its unique structure and function. The N-terminal domain's farnesylated cysteine residue and the C-terminal domain's cysteine residue make it a likely target for small molecules or antibodies. Additionally, the protein's localization to the plasma membrane and its involvement in the regulation of cellular processes make it a potential target for drugs that can modulate its stability or localization.

Biomarker Potential

DIP2A-IT1 has also been shown to be a potential biomarker for inflammatory neurodegenerative diseases. Its involvement in the regulation of inflammation and neurodegeneration makes it a potential target for antibodies or small molecules that can modulate its activity. Additionally, its expression and localization to various tissues make it a potential biomarker for these diseases.

Conclusion

DIP2A-IT1 is a protein that has been identified as a potential drug target and biomarker for inflammatory neurodegenerative diseases. Its unique structure and function make it an attractive target for drug development. Further studies are needed to determine its full potential as a drug and to develop biomarkers for its involvement in these debilitating conditions.

Protein Name: DIP2A Intronic Transcript 1

The "DIP2A-IT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DIP2A-IT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets